Carole Sable is an infectious disease physician with 25 years of development experience in academics, large pharma, and biotech companies. She is currently a clinical development consultant for antibiotic and antifungal biotech companies as well as a member of the Board of Directors of Basilea Pharmaceutica AG.
Her experience includes overseeing preclinical and clinical development, regulatory approvals, and launches of multiple compounds. She has extensive experience in-licensing and out-licensing anti-infective assets.
Formerly employed at Merck, her responsibilities there included leadership of multiple global programme teams and later as VP in the Infectious Disease Franchise overseeing the development strategy for all programmes in the Franchise.
She was also Chief Medical Officer at several successful biotech companies, including Novexel (acquired by Astra Zeneca), Vitae (acquired by Allergan), Arixa (acquired by Pfizer), and Scynexis (successful IPO). Notably, Carole led the development of caspofungin from phase 1 through worldwide regulatory approvals and launches for multiple indications. At Novexel, she led the development of ceftazidime-avibactam from initiation of clinical development through successful phase 2B studies. She designed innovative development approaches and introduced novel study designs for both programmes thereby demonstrating the strengths of each drug early in development.
Carole has been a member of several scientific advisory boards, including the Novo REPAIR Impact Fund, and has served as a scientific advisor for CARB-X. She has published over 30 research papers and reviews in peer reviewed journals. She received her medical degree in the USA at Jefferson Medical College in Philadelphia and her internal medicine residency and Infectious Disease Fellowship at the University of Virginia in Charlottesville. Prior to her move to the Pharmaceutical Industry, she was on faculty at the University of Virginia in the Division of Infectious Diseases, Department of Internal Medicine.